Why Ozempic shouldn't ruin an appetite for CSL shares

Could CSL be immune to Ozempic's expanding range of uses.

| More on:
Woman flexes muscles after donating blood.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is sliding lower on Monday as management tries to clear the air.

Feeling the squeeze, shares in the biotech heavyweight are down 0.6% to $239.93 amid the company's capital markets day. The briefing to investors and analysts is a whole day's affair to provide more in-depth insights across the different divisions of CSL.

One statement during this morning's proceedings was directed at worries regarding how weight-loss drugs, such as Ozempic, might eat into CSL's kidney disease business (CSL Vifor).

Disruption afoot?

On Thursday last week, CSL shares took a nasty 6.3% tumble after Novo Nordisk hinted at possible kidney benefits resulting from the use of glucagon-like peptide-1 (GLP-1) medications, such as Ozempic, following a trial involving their injectable semaglutide.

In a swift response, investors applied selling pressure to the Australian plasma behemoth due to its exposure to treating chronic kidney disease and related illnesses through its Vifor acquisition. As a result, the CSL share price gave way to a new 52-week low.

Today, CSL CEO Paul McKenzie addressed the matter directly, stating:

There's been a lot of talk about GLP-1s […] To give you the punchline, based on the high-level results, we do not see GLP-1s as having a material impact on the business.

Interestingly, the CSL Vifor section of the presentation focused heavily on iron deficiency and patient blood management. Whereas renal disease was a relatively brief mention, contained to a single presentation slide.

CSL Vifor general manager Hervé Gisserot reinforced the view that GLP-1s are not a concern. Specifically, Gisserot said, "In our view, as already stated by Paul, the renal disease market won't be disrupted by GLP-1."

Brokers still keen on CSL shares

Some brokers have come forward with updates on CSL shares following the news from Novo Nordisk. Much like management, these brokers have not been scared away from the vaccine and plasma powerhouse amid the developments in GLP-1s.

Firstly, analysts at Citi have retained their buy rating and a $325 price target. The team highlighted that CSL as a group only derives approximately 7% of its revenue from the nephrology area of its business.

Secondly, UBS analyst Sujit Dey estimates Vifor to constitute roughly 15% of group revenue. Yet, even at a higher estimate, Dey believes the $7 billion wiped from CSL's market capitalisation exceeds the maximum possible impact in the event of disruption.

As of today, CSL shares are down 15.2% since the beginning of 2023.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Novo Nordisk. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Exhausted young Caucasian woman lying on comfortable sofa in living room sleeping after hard-working day, tired millennial female fall asleep on couch at home, take nap or daydream, fatigue concept
Healthcare Shares

ResMed shares are in a two-month lull. Is this a chance to buy?

ResMed shares are still trading below the price targets of several brokers.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Healthcare Shares

Botanix shares jump on FDA approval and $70m capital raising

Investors are responding positively to some very big news.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Botanix Pharmaceuticals share price on watch amid FDA news and 'transformative event'

Big news has just been announced from this clinical dermatology company.

Read more »

Three health professionals at a hospital smile for the camera.
52-Week Highs

3 ASX healthcare shares smashing new 52-week highs today

The buying continues for these healthcare darlings.

Read more »

woman sitting at desk holding hand up in stop motion
Healthcare Shares

Guess which high-flying ASX All Ords stock was just halted ahead of a key FDA decision

The ASX All Ords stock is awaiting an important announcement from the US FDA.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Is the slashed Sonic Healthcare share price a 'buying opportunity'?

Is this stock a healthy opportunity?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Some big news is getting investors excited on Tuesday. What's happening?

Read more »